Selection of direct-acting antiviral agents in treatment of chronic hepatitis C patients with renal dysfunction
10.3969/j.issn.1001-5256.2018.02.007
- VernacularTitle:慢性丙型肝炎合并肾功能不全患者直接抗病毒药物治疗的选择
- Author:
Jianhong CHEN
1
;
Xiaoyuan XU
Author Information
1. 北京大学第一医院感染疾病科
- Keywords:
hepatitis C chronic;
renal insufficiency;
hemodiafiltration;
antiviral agents
- From:
Journal of Clinical Hepatology
2018;34(2):251-254
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of hepatitis C virus infection is commonly seen in patients with renal dysfunction (RD),especially those with end-stage renal disease on hemodialysis (HD),among whom the incidence and mortality of liver diseases increase.The development of direct-acting antiviral agents has revolutionized the therapy for chronic hepatitis C (CHC) with a sustained virologic response rate of ＞ 90％ and a low rate of adverse events.Grazoprevir/elbasvir,paritaprevir/ritonavir + ombitasvir + dasabuvir,glecaprevir/pibrentasvir,or daclatasvir + asunaprevir regimen is recommended in CHC patients with RD and HD,while the sofosbuvir-based regimen is not recommended.
